|
|
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors
This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
一项AXT-1003治疗晚期恶性肿瘤患者的开放标签、多中心、I期安全性研究
[Translation] An open-label, multicenter, phase I safety study of AXT-1003 in patients with advanced malignancies
本研究旨在观察AXT-1003在晚期恶性肿瘤患者中的安全性,确定研究药物的MTD和RP2D,评估研究药物的药代动力学特征,并初步探索研究药物的抗肿瘤活性。
[Translation] This study aims to observe the safety of AXT-1003 in patients with advanced malignant tumors, determine the MTD and RP2D of the study drug, evaluate the pharmacokinetic characteristics of the study drug, and preliminarily explore the anti-tumor activity of the study drug.
An Open-Label, Multicenter, Phase I Study of AXT-1003 as a Single Agent in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.
100 Clinical Results associated with Axter Therapeutics (Beijing) Co., Ltd.
0 Patents (Medical) associated with Axter Therapeutics (Beijing) Co., Ltd.
100 Deals associated with Axter Therapeutics (Beijing) Co., Ltd.
100 Translational Medicine associated with Axter Therapeutics (Beijing) Co., Ltd.